Abbvie Inc (ABBV) Fair Value

ABBV

Compare Earnings: May 31, 2026

Abbvie Inc

Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio.

Did you know?

Generated $14.7 in free cash flow for every $1 of capital expenditure in FY25.

Current Price

$208.84

-2.86%

GoodMoat Value

$131.68

36.9% overvalued

Profile

Valuation (TTM)

Market Cap$369.10B

P/E87.34

EV$424.43B

P/B—

Shares Out1.77B

P/Sales6.04

Revenue$61.16B

EV/EBITDA24.85

Abbvie Inc (ABBV)

Abbvie Inc — Fair Value

ABBV · NYSE · Healthcare

$208.84-2.86%

GoodMoat Target

$131.68Caution-36.9% margin of safety

“With a P/E exceeding 88, AbbVie's current valuation offers no margin of safety regardless of its pharmaceutical franchise quality or dividend history.”

— In the voice of Graham

What is the Fair Value?

Estimate fair value using the Graham Number, earnings-based model, and PEG-adjusted valuation. Three independent methods averaged together.

Key Metrics

Market Cap

$369.10B

P/E Ratio

87.34

Forward P/E

—

EPS

$2.36

PEG Ratio

-0.01

Book Value

$-1.85

Dividend Yield

3.16%

Profit Margin

6.91%

ROE

—

Fair Value Estimate

Average Fair Value

$99.29

Upside

-52.5%

Graham Number

√(22.5 × EPS × Book Value)

—

Earnings-Based

Future earnings discounted to present

$185.13

-11.4%

PEG-Adjusted

Fair P/E at PEG ratio of 1.0

$13.46

-93.6%

Adjust Parameters

Free account • No credit card required

Discount Rate (%)

Projection Years